{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:02:55Z","timestamp":1785358975994,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijgc.2025.104449","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:08:14Z","timestamp":1767168494000},"page":"104449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interval versus primary cytoreductive surgery in BRCA-mutated advanced-stage ovarian\/peritoneal\/tubal carcinoma"],"prefix":"10.1016","volume":"36","author":[{"given":"Peter G.","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3341-6830","authenticated-orcid":false,"given":"Meng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"DeBernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-6626","authenticated-orcid":false,"given":"Chad M.","family":"Michener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"AlHilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-7824","authenticated-orcid":false,"given":"Roberto","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ijgc.2025.104449_bib1","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/1097-0142(19821115)50:10<1979::AID-CNCR2820501002>3.0.CO;2-D","article-title":"Clinical cancer research: an embattled species","volume":"50","author":"Frei","year":"1982","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.104449_bib2","first-page":"393","article-title":"Neoadjuvant chemotherapy in advanced ovarian cancer","volume":"17","author":"Onnis","year":"1996","journal-title":"Eur J Gynaecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.104449_bib3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"9990","key":"10.1016\/j.ijgc.2025.104449_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ijgc.2025.104449_bib5","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.104449_bib6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ygyno.2016.06.013","article-title":"FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited","volume":"142","author":"Ataseven","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"32","key":"10.1016\/j.ijgc.2025.104449_bib7","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1200\/JCO.2016.68.1239","article-title":"Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer","volume":"34","author":"Meyer","year":"2016","journal-title":"J Clin Oncol."},{"issue":"7","key":"10.1016\/j.ijgc.2025.104449_bib8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.104449_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1052628","article-title":"Nomogram to predict postoperative complications after cytoreductive surgery for advanced epithelial ovarian cancer: a multicenter retrospective cohort study","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.104449_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2020.08.022","article-title":"Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer","volume":"161","author":"Di Donato","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.104449_bib11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.104449_bib12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"21","key":"10.1016\/j.ijgc.2025.104449_bib13","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.104449_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ygyno.2021.04.014","article-title":"Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: a retrospective multicenter study (MITO 21)","volume":"161","author":"Artioli","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.104449_bib15","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ygyno.2021.07.010","article-title":"The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma","volume":"162","author":"Kim","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.104449_bib16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.canlet.2015.08.028","article-title":"High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation","volume":"369","author":"Gorodnova","year":"2015","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.ijgc.2025.104449_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ygyno.2015.07.101","article-title":"Outcome of neoadjuvant chemotherapy in BRCA1\/2 mutation positive women with advanced-stage M\u00fcllerian cancer","volume":"139","author":"Mahdi","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.104449_bib18","doi-asserted-by":"crossref","first-page":"334.e1","DOI":"10.1016\/j.ajog.2017.05.036","article-title":"BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study","volume":"217","author":"Petrillo","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.104449_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13048-019-0511-7","article-title":"Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer","volume":"12","author":"Kim","year":"2019","journal-title":"J Ovarian Res"},{"issue":"4","key":"10.1016\/j.ijgc.2025.104449_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology\/Gynecologic Oncology Group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ijgc.2025.104449_bib21","doi-asserted-by":"crossref","first-page":"676.e1","DOI":"10.1016\/j.ajog.2007.10.495","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.104449_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ygyno.2019.07.011","article-title":"A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy","volume":"154","author":"Bartels","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.104449_bib23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ygyno.2018.10.044","article-title":"Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery","volume":"152","author":"Meyer","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"suppl 17","key":"10.1016\/j.ijgc.2025.104449_bib24","article-title":"TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7)","volume":"43","author":"Mahner","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.104449_bib25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.104449_bib26","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/IGC.0000000000000675","article-title":"Restaging and survival analysis of 4036 ovarian cancer patients according to the 2013 FIGO classification for ovarian, fallopian tube, and primary peritoneal cancer","volume":"26","author":"Rosendahl","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.104449_bib27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ygyno.2022.07.004","volume":"166","author":"Pitiyarachchi","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.104449_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/AOG.0000000000003086","article-title":"Nomogram for predicting individual survival after recurrence of advanced-stage, high-grade ovarian carcinoma","volume":"133","author":"Rose","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.104449_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2503573X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2503573X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:21:53Z","timestamp":1785356513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2503573X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1048891X2503573X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.104449","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interval versus primary cytoreductive surgery in BRCA-mutated advanced-stage ovarian\/peritoneal\/tubal carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.104449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104449"}}